Neuronal oxidative damage from activated innate immunity is EP2 receptor‐dependent
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Increase in prostaglandin (PG) E 2 levels and oxidative damage are associated with diseases of brain that involve activation of innate immunity. We tested the hypothesis that cerebral oxidative damage resulting from activation of innate immunity with intracerebroventricular (icv) lipopolysaccharide (LPS) is dependent on PGE 2‐mediated signaling. We measured two quantitative in vivo biomarkers of lipid peroxidation: F 2‐isoprostanes (IsoPs) that derive from arachidonic acid (AA) that is uniformly distributed in all cell types in brain, and F 4‐neuroprostanes (NeuroPs) that derive from docosahexaenoic acid (DHA) that is highly concentrated in neuronal membranes. LPS stimulated delayed elevations in cerebral F 2‐IsoPs and F 4‐NeuroPs that were completely suppressed by indomethacin or ibuprofen pre‐treatment. LPS‐induced cerebral oxidative damage was abolished by disruption of subtype 2 receptor for PGE 2 (EP 2). In contrast, initial oxidative damage from icv kainic acid (KA) was more rapid than with LPS also was completely suppressed by indomethacin or ibuprofen pre‐treatment but was independent of EP 2 receptor activation. The protective effect of deleting the EP 2 receptor was not associated with changes in cerebral eicosaniod production, but was partially related to reduced induction of nitric oxide synthase (NOS) activity. These results suggest the EP 2 receptor as a therapeutic target to limit oxidative damage from activation of innate immunity in cerebrum.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity
Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., Findlay, K. A., Smith, T. E., Murphy, M. P., Bulter, T., et al. (2001) · Nature · doi:10.1038/35102591 · Cited by 1,388 · cited 6×
“…the effects of indomethacin and ibuprofen in the experiments described above, including suppression of PGE2 production, suppres- sion of other COX products, and COX-independent actions of NSAIDs that include antioxidant activity (Hamburger and McCay 1990; Asanuma et al. 2001; Weggen et al. 2001).”
BackgroundInfluentialMcGeer, P. L., Schulzer, M., & McGeer, E. G. (1996) · Neurology · doi:10.1212/wnl.47.2.425 · Cited by 1,367 · cited 1×
“Perhaps the greatest current interest in the role of NSAIDs in CNS disease is their potential to reduce the risk of developing Alzheimer’s disease (Andersen et al. 1995; McGeer et al. 1996; Stewart et al. 1997; in tVeld et al. 2000, 2001).”
BackgroundNonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
in 't Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M. B., & Stricker, B. H. C. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010178 · Cited by 1,196
Risk of Alzheimer's disease and duration of NSAID use
Stewart, W. F., Kawas, C., Corrada, M., & Metter, E. J. (1997) · Neurology · doi:10.1212/wnl.48.3.626 · Cited by 1,132 · cited 1×
“Perhaps the greatest current interest in the role of NSAIDs in CNS disease is their potential to reduce the risk of developing Alzheimer’s disease (Andersen et al. 1995; McGeer et al. 1996; Stewart et al. 1997; in tVeld et al. 2000, 2001).”
BackgroundProstanoid Receptors: Subtypes and Signaling
Breyer, R. M., Bagdassarian, C. K., Myers, S. A., & Breyer, M. D. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.661 · Cited by 1,011 · cited 1×
“Because of these multiple receptors, PGE2 commonly has versatile and often opposing actions in many tissues and cells (reviewed in Breyer et al. 2001.).”
BackgroundSelf-citationExcitotoxicity and nitric oxide in parkinson's disease pathogenesis
Beal, M. F. (1998) · Annals of Neurology · doi:10.1002/ana.410440716 · Cited by 283
Xie, Z., Wei, M., Morgan, T. E., Fabrizio, P., Han, D., Finch, C. E., & Longo, V. D. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-09-03484.2002 · Cited by 272
Cited by
Prostaglandins and Inflammation
Ricciotti, E., & FitzGerald, G. A. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.207449 · Cited by 3,803
Hata, A. N., & Breyer, R. M. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.06.003 · Cited by 840
Self-citationWoodward, D. F., Jones, R. L., & Narumiya, S. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003517 · Cited by 443
Neuroprotective Function of the PGE2EP2 Receptor in Cerebral Ischemia
McCullough, L., Wu, L., Haughey, N., Liang, X., Hand, T., Wang, Q., Breyer, R. M., & Andreasson, K. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.4485-03.2004 · Cited by 361
Self-citationF2-Isoprostanes as markers of oxidative stress in vivo: An overview
Milne, G. L., Musiek, E. S., & Morrow, J. D. (2005) · Biomarkers · doi:10.1080/13547500500216546 · Cited by 312
Self-citation
Metadata
- Authors
- Montine, T. J., Milatovic, D., Gupta, R. C., Valyi‐Nagy, T., Morrow, J. D., & Breyer, R. M.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2002-10
- Volume
- 83
- Issue
- 2
- Pages
- 463-470
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W2132246418
- Cited by
- 133
- References
- 7
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neuronal oxidative damage from activated innate immunity is EP2 receptor‐dependent. https://app.cochat.ai/papers/10.1046/j.1471-4159.2002.01157.x
- The paper
- Montine, T. J., Milatovic, D., Gupta, R. C., Valyi‐Nagy, T., Morrow, J. D., & Breyer, R. M. (2002). Neuronal oxidative damage from activated innate immunity is EP2 receptor‐dependent. Journal of Neurochemistry. https://doi.org/10.1046/j.1471-4159.2002.01157.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.